The Hirshberg Foundation is pleased to announce that Dr. Tim Donahue will attend the 19th Annual Symposium on Pancreatic Cancer to share a 2025 progress report on pancreatic cancer.
Dr. Donahue will provide an update on promising new treatment developments for pancreatic cancer. These include advancements in earlier diagnosis strategies, surgical interventions, targeted therapies, and immunotherapies, which are beginning to show potential for this challenging disease. He will also review state-of-the-art approaches to medical and comprehensive patient care offered at the Agi Hirshberg Center for Pancreatic Diseases.
Dr. Timothy Donahue serves as Chief of the Division of Surgical Oncology and Professor of Surgery at the David Geffen School of Medicine at UCLA. He also holds a joint appointment in the Department of Molecular and Medical Pharmacology, which supports his robust research program. As the Medical Director for Cancer Services, Dr. Donahue oversees all cancer-related care across the UCLA Health System. In his role as Director of the UCLA Agi Hirshberg Center for Pancreatic Diseases, Dr. Donahue is a highly skilled pancreatic surgeon, performing three to four pancreatic surgeries per week. He and his team tackle some of the most complex cases, achieving outcomes that rank among the best in the world. Dr. Donahue is deeply committed to providing patients with pancreatic cancer state-of-the-art care and personalized treatment. Beyond his clinical expertise, Dr. Donahue leads a National Institutes of Health-funded research laboratory as Principal Investigator. His research focuses on developing innovative drugs and improving treatment strategies for pancreatic cancer. He collaborates extensively with researchers across UCLA to advance the scientific understanding and management of this challenging disease.
An important presentation for our pancreatic cancer community, we are so happy to have Dr. Donahue present Pancreatic Cancer Progress Report 2025 at the 19th Annual Symposium.
